Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Small-Cap · New York Life Investments

NYLI Fiera SMID Growth Fund Class C (APSLX)

Ticker APSLX · Since 2023-07-24 · · Holdings as of Jul 31, 2026

Expense ratio
2.05%$205/yr per $10k
1-yr return
+3.5%as of Dec 2025
Net assets
$201.4Mall share classes
Holdings
79

Bottom line

Is APSLX a good fund? The bottom line

APSLX is the Class C share class of NYLI Fiera SMID Growth Fund, a managed small-cap mutual fund from New York Life Investments.

Its expense ratio is 2.05% — about $205 a year on every $10,000 invested, more expensive than 97% of small-cap funds we track.

It returned +3.5% over one year (as of Dec 31, 2025, per its prospectus).

With $201 million in net assets and 79 holdings, its largest position is JFrog Ltd. (3.7%) and the top 10 make up 23.5% of the portfolio.

What stands out

  • No front-end sales load

What to watch

  • Expensive for its category (2.05%)
  • 12b-1 marketing fee of 1% a year

Updated Nov 19, 2026

What APSLX invests in

The Fund seeks long term capital growth.

Fiera Capital Inc. (the Subadvisor) seeks to achieve the Funds investment objective by investing in a diversified portfolio of common stocks of companies believed to be small- and mid-cap growth-oriented companies that are selected for their long-term capital appreciation potential and which the Subadvisor expects to grow faster than the U.S. economy. The Fund considers an issuer to be a small- or mid-capitalization issuer if it has a market capitalization, at the time of purchase, within the range of Russell 2500 TM Growth Index (which as of December 31, 2025 ranged from $12.5 million to $37 billion) or the Russell Midcap Growth Index (which as of December 31, 2025 ranged from $1 billion to $101.6 billion). These ranges are subject to change over time due to changes in market and/or economic conditions. The Fund may also invest in exchange-traded funds (ETFs). The Fund may also invest…

From the fund's prospectus (filed Feb 26, 2026).

APSLX performance

Average annual total returns
1 yr5 yr10 yr
APSLX+3.5%——
Small-Cap median+7.6%+7.0%+9.2%

Source: Fund prospectus, as of Dec 31, 2025

Full APSLX performance history →

What APSLX costs

On a $10,000 investment, APSLX's 2.05% expense ratio costs about $205 a year. The prospectus estimates $2,188 in total costs over 10 years (assuming 5% annual returns). The median small-cap fund charges 0.99%.

See the full APSLX fee table →

APSLX top 10 holdings

#Holding% of fund
1JFrog Ltd.3.71%
2BWX Technologies, Inc.2.63%
3EMCOR Group, Inc.2.40%
4Neurocrine Biosciences, Inc.2.27%
5Stifel Financial Corp.2.23%
6MongoDB, Inc.2.12%
7Argenx SE2.09%
8Insmed, Inc.2.04%
9Expedia Group, Inc.2.00%
10Lattice Semiconductor Corp.1.97%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 23.5% of the fund. See all top 25 holdings and asset mix →

Alternatives to APSLX

More funds like APSLX →

APSLX FAQ

What is the expense ratio of APSLX?
APSLX's expense ratio is 2.05%, which works out to about $205 a year for every $10,000 invested. The prospectus estimates total costs of $2,188 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is APSLX a good investment?
It depends on your goals, but the data points to: no front-end sales load; expensive for its category (2.05%); 12b-1 marketing fee of 1% a year. This is general information, not personalized advice.
What does APSLX hold?
APSLX's largest holdings are JFrog Ltd. (3.7%), BWX Technologies, Inc. (2.6%), EMCOR Group, Inc. (2.4%), Neurocrine Biosciences, Inc. (2.3%), Stifel Financial Corp. (2.2%). It holds 79 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
Does APSLX have a sales load?
No. APSLX has no front-end sales charge. It may charge a deferred sales charge of up to 1% if sold early.
Who manages APSLX?
APSLX is offered by New York Life Investments through New York Life Investments Funds Trust.